MK-8510
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 27, 2023
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Merck Sharp & Dohme LLC | N=24 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Monotherapy • Trial withdrawal • Human Immunodeficiency Virus • Infectious Disease
January 26, 2023
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
Monotherapy • New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease
1 to 2
Of
2
Go to page
1